Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Paragon 28 to Report Second Quarter 2024 Financial Results on August 8, 2024

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.

Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 389675. Live audio of the webcast will be available on the “Investors” section of the Company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.

Upcoming Conference Participation

Paragon 28 also announced the Company’s management team will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, at 8:00 a.m. Eastern Time / 6:00 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company’s website at ir.paragon28.com.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Contacts

Investor Contact:

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (720) 912-1332

mbrinckman@paragon28.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.